<VariationArchive VariationID="2424390" VariationName="NC_000023.10:g.(?_119565178)_(119576537_?)del" VariationType="Deletion" Accession="VCV002424390" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1939550" VariationID="2424390">
      <GeneList>
        <Gene Symbol="LAMP2" FullName="lysosomal associated membrane protein 2" GeneID="3920" HGNC_ID="HGNC:6501" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq24</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="120426148" stop="120469349" display_start="120426148" display_stop="120469349" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="119560002" stop="119603203" display_start="119560002" display_stop="119603203" Strand="-" />
          </Location>
          <OMIM>309060</OMIM>
          <Haploinsufficiency last_evaluated="2021-02-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LAMP2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-02-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LAMP2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000023.10:g.(?_119565178)_(119576537_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq24</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" innerStart="119565178" innerStop="119576537" display_start="119565178" display_stop="119576537" variantLength="11360" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.(?_119565178)_(119576537_?)del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.(?_119565178)_(119576537_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000023.10:g.(?_119565178)_(119576537_?)del AND Danon disease" Accession="RCV003107623" Version="3">
        <ClassifiedConditionList TraitSetID="2823">
          <ClassifiedCondition DB="MedGen" ID="C0878677">Danon disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-04-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-04-15" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">27816333</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2823" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1699" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PSEUDOGLYCOGENOSIS II</ElementValue>
                <XRef Type="MIM" ID="300257" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GSD IIb</ElementValue>
                <XRef Type="MIM" ID="300257" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">LYSOSOMAL GLYCOGEN STORAGE DISEASE WITHOUT ACID MALTASE DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="300257" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudoglycogenosis 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen storage disease limited to the heart</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen storage cardiomyopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen storage disease type 2b (formerly)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lysosomal glycogen storage disease without acid maltase deficiency (formerly)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GSD2B (formerly)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Danon disease</ElementValue>
                <XRef ID="Danon+Disease/2114" DB="Genetic Alliance" />
                <XRef ID="MONDO:0010281" DB="MONDO" />
                <XRef ID="419097006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Vacuolar cardiomyopathy and myopathy X-linked</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Antopol disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen Storage Disease Type IIb</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GSD2B</ElementValue>
                <XRef Type="MIM" ID="300257" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9730" />
                <XRef ID="9730" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Danon disease is a multisystem condition with predominant involvement of the heart, skeletal muscles, and retina, with overlying cognitive dysfunction. Males are typically more severely affected than females. Males usually present with childhood onset concentric hypertrophic cardiomyopathy that is progressive and often requires heart transplantation. Rarely, hypertrophic cardiomyopathy can evolve to resemble dilated cardiomyopathy. Most affected males also have cardiac conduction abnormalities. Skeletal muscle weakness may lead to delayed acquisition of motor milestones. Learning disability and intellectual disability, most often in the mild range, are common. Additionally, affected males can develop retinopathy with subsequent visual impairment. The clinical features in females are broader and more variable. Females are more likely to have dilated cardiomyopathy, with a smaller proportion requiring heart transplantation compared to affected males. Cardiac conduction abnormalities, skeletal muscle weakness, mild cognitive impairment, and pigmentary retinopathy are variably seen in affected females.</Attribute>
                <XRef ID="NBK554742" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">32134616</ID>
                <ID Source="BookShelf">NBK554742</ID>
              </Citation>
              <XRef ID="34587" DB="Orphanet" />
              <XRef ID="C0878677" DB="MedGen" />
              <XRef ID="MONDO:0010281" DB="MONDO" />
              <XRef Type="MIM" ID="300257" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7073236" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_002294.2_X_Deletion (exons 7-9)|MedGen:C0878677" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003794612" DateUpdated="2024-06-09" DateCreated="2023-02-13" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">27816333</ID>
          </Citation>
          <Comment>This variant has not been reported in the literature in individuals affected with LAMP2-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 7-9 of the LAMP2 gene, which includes the termination codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product. This variant disrupts a region of the LAMP2 protein in which other variant(s) (p.Gln353*) have been determined to be pathogenic (PMID: 27816333; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LAMP2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.(?_119565178)_(119576537_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0878677" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7073236" TraitType="Disease" MappingType="XRef" MappingValue="C0878677" MappingRef="MedGen">
        <MedGen CUI="C0878677" Name="Danon disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

